基于分子特征的原发性干燥综合征患者独特亚群
该研究基于基因表达微阵列和血清因子检测,将符合AECG分类标准且有系统表现的原发性干燥综合征患者分为三个分子亚群:集群1无显著IFN或炎症模块升高,集群2有强IFN和炎症特征及多种血浆蛋白升高,集群3有中度IFN升高但炎症受抑。抗Ro/SSA和抗La/SSB存在于所有三个集群中,提示分子分型可为临床试验患者选择和治疗决策提供信息。
要点
- 原发性干燥综合征患者可基于IFN和炎症相关转录模块分为三个分子亚群。
- 集群2显示强IFN和炎症特征,伴IP-10/CXCL10、MIG/CXCL9、BLyS和LIGHT升高。
- 抗Ro/SSA和抗La/SSB存在于所有三个集群中,不能单独区分分子亚群。
核心结论
- 涵盖IFN、炎症和其他特征的分子谱可将原发性干燥综合征患者分为不同集群,未来可能用于临床试验患者选择和指导治疗决策。
研究设计与样本
- 研究纳入符合美国-欧洲共识组分类标准、至少有一种系统表现且刺激唾液流率≥0.1 ml/min的原发性干燥综合征患者,从血液基因表达微阵列数据(n=47)中衍生相关转录模块,并使用无偏随机森林建模方法基于分子信息对患者进行聚类。
主要发现
- 转录模块区分出三个原发性干燥综合征患者集群:集群1无显著IFN或炎症模块升高;集群2显示强IFN和炎症模块网络特征,以及IP-10/CXCL10、MIG/CXCL9、BLyS(BAFF)和LIGHT血浆蛋白水平高;集群3样本显示IFN模块中度升高但炎症模块受抑,IP-10/CXCL10和B细胞吸引趋化因子1/CXCL13升高,并有MIG/CXCL9、IL-1α和IL-21升高的趋势。
- 抗Ro/SSA和抗La/SSB存在于所有三个集群中。
临床怎么用
- 分子谱可能有助于在临床试验中筛选患者并指导治疗决策,但尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To address heterogeneity complicating primary SS (pSS) clinical trials, research and care by characterizing and clustering patients by their molecular phenotypes. METHODS: pSS patients met American-European Consensus Group classification criteria and had at least one systemic manifestation and stimulated salivary flow of ⩾0.1 ml/min. Correlated transcriptional modules were derived from gene expression microarray data from blood (n = 47 with appropriate samples). Patients were clustered based on this molecular information using an unbiased random forest modelling approach. In addition, multiplex, bead-based assays and ELISAs were used to assess 30 serum cytokines, chemokines and soluble receptors. Eleven autoantibodies, including anti-Ro/SSA and anti-La/SSB, were measured by Bio-Rad Bioplex 2200. RESULTS: Transcriptional modules distinguished three clusters of pSS patients. Cluster 1 showed no significant elevation of IFN or inflammation modules. Cluster 2 showed strong IFN and inflammation modular network signatures, as well as high plasma protein levels of IP-10/CXCL10, MIG/CXCL9, BLyS (BAFF) and LIGHT. Cluster 3 samples exhibited moderately elevated IFN modules, but with suppressed inflammatory modules, increased IP-10/CXCL10 and B cell-attracting chemokine 1/CXCL13 and trends toward increased MIG/CXCL9, IL-1α, and IL-21. Anti-Ro/SSA and anti-La/SSB were present in all three clusters. CONCLUSION: Molecular profiles encompassing IFN, inflammation and other signatures can be used to separate patients with pSS into distinct clusters. In the future, such profiles may inform patient selection for clinical trials and guide treatment decisions.
引用
- James JA, Guthridge JM, Chen H, et al. Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020. PMID: 31497844. doi:10.1093/rheumatology/kez335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。